E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Moderate to severe plaque psoriasis |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10037153 |
E.1.2 | Term | Psoriasis |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To establish a dose-response efficacy profile of AMG 827 compared with placebo as measured by the percent improvement from baseline in Psoriasis Area and Severity Index (PASI) score at week 12 and to identify an appropriate dose regimen for future trials. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy of AMG 827 as measured by the following: − The proportion of subjects with a PASI 75 at week 12 − The proportion of subjects with a PASI 50, 90, and 100 at week 12 − The proportion of subjects with a static physician’s global assessment (sPGA) of clear (0) or clear/almost clear (0 or 1) at week 12 − Body surface area (BSA) involvement at weeks 12 To evaluate the short term safety profile of AMG 827 in subjects with moderate to severe psoriasis To characterize the pharmacokinetics (PK) of AMG 827 in subjects with moderate to severe psoriasis |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
|
E.3 | Principal inclusion criteria |
Subject is capable of understanding and giving written, voluntary informed consent before study screening. Male or female ≥ 18 and ≤ 70 years of age at time of screening. Subject has had stable moderate to severe plaque psoriasis for at least 6 months (eg, no morphology changes or significant flares of disease activity in the opinion of the investigator). Subject has received at least 1 previous phototherapy or systemic psoriasis therapy, ie, PUVA therapy, cyclosporine or methotrexate. Subject has involved BSA ≥ 10% and PASI ≥ 12 at screening and at baseline. Subject has a negative test for hepatitis B virus (HBV) surface antigen, hepatitis C virus (HCV) antibody, and HIV. Subject has a negative serum pregnancy test within 28 days before initiating IP for female subjects (except those at least 3 years postmenopausal or surgically sterile) and a negative urine pregnancy test at baseline. Subject has a negative purified protein derivative (PPD) test within 30 days prior to the first IP dose. Tuberculin skin tests should be considered positive when they have ≥ 5 mm of induration at 48 to 72 hours after test is placed. Subjects with a positive tuberculin skin test (if ≤ 14 mm of induration) may enroll if they have a history of Bacillus Calmette-Guerin vaccination with a negative Quantiferon test in the past year, no symptoms per tuberculosis worksheet, and a negative chest X-ray. |
|
E.4 | Principal exclusion criteria |
Skin disease related Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced, or medication-exacerbated psoriasis. Evidence of skin conditions at the time of the screening visit (eg, eczema, guttate psoriasis) that would interfere with evaluations of the effect of IP on psoriasis. Other medical conditions Subject has a planned surgical intervention for a pretreatment condition within the duration of the study, including the follow-up period. Subject has any active CTCAE grade 2 (localized infection, local intervention indicated) or higher infection (including chronic or localized infections) within 30 days prior to screening, at screening, or during screening period prior to first IP dose. Subject has a serious infection, defined as requiring hospitalization or IV antibiotics within 8 weeks before screening. Subject has recurrent or chronic infections, defined as ≥ 3 infections requiring anti-microbials over the past 12 months prior to screening. Subject has a significant concurrent medical condition, including: − Type 1 diabetes. − Poorly controlled type 2 diabetes (Hemoglobin A1c > 8.5). − Symptomatic heart failure (New York Heart Association class II, III, or IV). − Myocardial infarction within the last year. − Current or history of unstable angina pectoris within the last year. − Uncontrolled hypertension as defined by resting blood pressure > 150/90 mmHg prior to randomization (confirmed by a repeat assessment). − Severe chronic pulmonary disease (eg, requiring oxygen therapy). − Major chronic inflammatory disease or connective tissue disease other than psoriasis with or without arthritis. − Multiple sclerosis or any other demyelinating disease. − Active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma, or history of cancer (except successfully treated in situ cervical cancer or squamous or basal cell carcinoma of the skin). − Any condition that, in the opinion of the investigator, might cause this study to be detrimental to the subject. Subject is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the subject’s last study visit including the 30-day follow-up period. Female subject is not willing to abstain from sexual intercourse or use 2 highly effective forms of birth control for the duration of the study including the follow-up period (except women at least 3 years postmenopausal or surgically sterile). Highly effective methods of birth control for women include but are not limited to birth control pills, Depo-Provera® injections, contraceptive implants, or occlusive cap (barrier method) in combination with barrier methods used by the man. Male subject is not willing to abstain from sexual intercourse or use 2 highly effective forms of birth control for the duration of the study including the follow-up period, plus an additional 4 weeks (except for men who are surgically sterile or whose female partners are at least 3 years postmenopausal or surgically sterile). Highly effective methods of birth control include but are not limited to a condom in combination with hormonal birth control or barrier methods used by the woman. Male subject (including vasectomised males) with a pregnant female partner is not willing to use effective methods to ensure that an unborn child is not exposed to AMG 827 via semen. Effective methods to ensure that an unborn child is not exposed to AMG 827 via semen include condoms or abstinence. Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures. Laboratory abnormalities Subject has laboratory abnormalities at screening, including: − Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 1.5x the upper limit of normal. − Serum total bilirubin ≥ 1.5 mg/dL. − Hemoglobin < 11 g/dL. − Platelet count < 125,000 /mm3. − White blood cell count < 3,000 cells/mm3. − Absolute neutrophil count (ANC) < 2000/mm3. − Estimated creatinine clearance < 50 mL/min (Cockroft-Gault formula, central lab will calculate value and provide to sites). − Any other laboratory abnormality, which, in the opinion of the investigator, will prevent the subject from completing the study or will interfere with the interpretation of the study results. AMG 827 contraindications or precautions Known or suspected sensitivity to mammalian cell-derived (ie, from Chinese hamster ovary) products or any components of the study drug. For further exclusion critieria please see protocol. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Percent improvement from baseline in PASI at week 12 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 0 |